Cargando…

Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion

Objectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegl, Ulrich J., Maier, Doris, Gonschorek, Oliver, Heyde, Christoph-Eckhard, Bühren, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: German Medical Science GMS Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582502/
https://www.ncbi.nlm.nih.gov/pubmed/26504725
http://dx.doi.org/10.3205/iprs000055
_version_ 1782391707793358848
author Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
author_facet Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
author_sort Spiegl, Ulrich J.
collection PubMed
description Objectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from a massive spasticity after traumatic spinal cord lesion. Conservative treatment options did not show satisfying results. All patients were injected a maximal dose of 2,000 units of botulinum toxin A in no more than 6 skeletal muscle groups. Clinical control examinations were performed after 2 weeks and after at least 2 years. Results: 6 patients reported a good or very good result. One patient offered increasing difficulty in walking for a short time after injection. 2 patients showed no beneficial effects. One patient experienced a modest temporary general weakness for 3 days. After 2 years, 3 patients showed improved function with persistent reduction of spasticity. In the other cases, the beneficial effect lasted for an average of 9 months. Conclusion: Botulinum toxin A injection seems to be an effective complementary therapy option in the treatment of spasticity of paraplegic patients with complete deficit of their motor function (ASIA A and B) and a spastic distribution pattern, effecting only a limited number of muscle groups. Caution has to be recommended for incomplete paretic patients, who are able to walk.
format Online
Article
Text
id pubmed-4582502
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher German Medical Science GMS Publishing House
record_format MEDLINE/PubMed
spelling pubmed-45825022015-10-26 Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion Spiegl, Ulrich J. Maier, Doris Gonschorek, Oliver Heyde, Christoph-Eckhard Bühren, Volker GMS Interdiscip Plast Reconstr Surg DGPW Article Objectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from a massive spasticity after traumatic spinal cord lesion. Conservative treatment options did not show satisfying results. All patients were injected a maximal dose of 2,000 units of botulinum toxin A in no more than 6 skeletal muscle groups. Clinical control examinations were performed after 2 weeks and after at least 2 years. Results: 6 patients reported a good or very good result. One patient offered increasing difficulty in walking for a short time after injection. 2 patients showed no beneficial effects. One patient experienced a modest temporary general weakness for 3 days. After 2 years, 3 patients showed improved function with persistent reduction of spasticity. In the other cases, the beneficial effect lasted for an average of 9 months. Conclusion: Botulinum toxin A injection seems to be an effective complementary therapy option in the treatment of spasticity of paraplegic patients with complete deficit of their motor function (ASIA A and B) and a spastic distribution pattern, effecting only a limited number of muscle groups. Caution has to be recommended for incomplete paretic patients, who are able to walk. German Medical Science GMS Publishing House 2014-12-10 /pmc/articles/PMC4582502/ /pubmed/26504725 http://dx.doi.org/10.3205/iprs000055 Text en Copyright © 2014 Spiegl et al. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/). You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Article
Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_full Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_fullStr Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_full_unstemmed Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_short Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_sort antispastic therapy with botulinum toxin type a in patients with traumatic spinal cord lesion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582502/
https://www.ncbi.nlm.nih.gov/pubmed/26504725
http://dx.doi.org/10.3205/iprs000055
work_keys_str_mv AT spieglulrichj antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT maierdoris antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT gonschorekoliver antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT heydechristopheckhard antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT buhrenvolker antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion